"Designing Growth Strategies is in our DNA"
The Japan tardive dyskinesia therapeutics market size was valued at USD 24.3 million in 2022. The market is projected to grow from USD 38.6 million in 2023 to USD 162.1 million by 2030, exhibiting a CAGR of 22.7% during the forecast period.
Tardive Dyskinesia (TD) is a movement disorder that occurs as a potentially serious adverse drug reaction to various psychotropic medications, especially antipsychotics. It is more commonly observed in patients treated with first-generation antipsychotics (FGAs) than with second-generation antipsychotics (SGAs), which are used for the treatment of psychiatric disorders.
The symptoms can be managed with the help of two drugs, as there is no known cure. The symptoms are managed through drugs belonging to the VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors) indicated to treat Huntington's disease or tardive dyskinesia. These two drugs are valbenazine and deutetrabenazine, which received approval from the U.S. Food and Drug Administration (FDA) in 2017 for this disease.
In the case of Japan, only valbenazine had received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of this condition in 2022. The approval status of the VMAT-2 inhibitors for this indication in Europe is inconsistent. Prolonged consumption of these medications increases the risk of tardive dyskinesia as a side effect.
The increasing prevalence of psychiatric disorders is expected to drive the demand for its treatment through medications such as antipsychotics. This is anticipated to drive effective therapeutic measures among psychiatric patients and surge the demand for approved medications indicated to treat this condition. Hence, the surge in demand for these drugs is likely to propel the market growth for tardive dyskinesia therapeutics during the forecast period.
Drop in Hospital Visits During COVID-19 Led to a Slower Market Growth
The impact of COVID-19 was visible in the healthcare sector as health was at the center of this unprecedented challenge. Due to the lockdowns implemented during the COVID-19 pandemic, a significant decline was witnessed in hospital visits as there was a lack of availability of healthcare services and procedures unrelated to COVID-19 due to safety precautions. This served as an impediment in diagnoses and providing subsequent treatments to psychotic patients.
During the lockdown restrictions, the government authorities attempted to maintain access to psychiatric care. However, the treatment of some patients who needed appropriate drug therapies was hampered.
The pandemic also hampered pharmaceutical companies' business as the process of obtaining critical treatment slowed down due to the closure of healthcare facilities for non-emergency procedures during the pandemic.
However, as the lockdown restrictions were eased, the resumption of healthcare facilities for patients diagnosed with certain psychotic disorders occurred. In terms of drug approval, the regulatory authorities reviewed the pending or delayed clinical data to provide approvals and expand treatment options for movement disorders.
Increased Transition from Off Label Treatments to Approved Treatments
For several decades, tardive dyskinesia was extensively considered as an untreatable drug-induced movement disorder associated with the pharmacotherapy of numerous psychiatric disorders resulting from the deployment of dopamine receptor-blocking agents, such as antipsychotics. The off-label treatments for this disease are dietary supplements, pharmacologic interventions, and non-pharmacologic treatment approaches available in Japan.
Before the approval of any medication for this disease, there was no fixed treatment, and the treatment regime usually involved lowering or reducing antipsychotic dosage or switching medications. However, these treatment approaches possessed a high risk of destabilizing the psychiatric condition of the patient population. Antioxidants and benzodiazepines are examples of some nonspecific interventions which were used.
The use of second-generation antipsychotics for the treatment of underlying mental health conditions reduced the risk of this condition. However, it did not eliminate it, leaving an unmet need for treatment for this disruptive movement disorder. In 2017, the treatment landscape for this disease significantly changed with the approval of vesicular monoamine transporter 2 (VMAT2) inhibitors by the U.S. FDA. The inhibitors offer treatment for involuntary movements and also help the encouragement of earlier intervention and diagnosis.
Request a Free sample to learn more about this report.
Increasing Patient Population of Mental Disorders to Propel Market Growth
The tardive dyskinesia therapeutics market growth is driven by the increasing prevalence of psychiatric disorders in Japan. Psychiatric disorders such as schizophrenia, bipolar disorder, depression, anxiety, and others are treated with certain drugs such as antipsychotics, and the long term use of these medications leads to this condition as a side effect.
The increasing patient population undergoing antipsychotic treatment is likely to increase the prevalence of this disease. This is anticipated to drive the demand for tardive dyskinesia therapeutics across the country during the forecast period.
Increasing Consumption of Antipsychotic Drugs to Drive Market Growth
Another factor responsible for driving the demand for tardive dyskinesia therapeutics is the growing consumption of antipsychotic drugs for the treatment of psychotic disorders. Antipsychotic drugs are commonly prescribed for schizophrenia, attention-deficit hyperactivity disorder (ADHD), epilepsy, and dementia, among others. The increasing prescription rate of antipsychotic medication among this patient population increases their risk of tardive dyskinesia.
The use of antipsychotics is expanding, which may lead to an increased number of tardive dyskinesia patients. This is anticipated to surge the demand for therapeutic measures approved for the treatment of this condition. This will subsequently drive the market growth during the forecast period.
Lack of Awareness Related to Tardive Dyskinesia to Limit Market Growth
One of the significant hindrances witnessed in the growth of tardive dyskinesia therapeutics is the lack of awareness about this disease and its limited treatment options among patients as well as among healthcare providers in Japan. A lack of awareness related to this condition will increase the burden of this disease and will also result in a restricted number of patients undergoing treatment. Furthermore, the stringent regulatory scenario limits the number of drugs approved for this condition, subsequently restricting the Japan tardive dyskinesia therapeutics market growth.
Moreover, there is a lack of approved drugs indicated for the treatment of this disease in Japan compared to other regions. For instance, valbenazine and deutetrabenazine were approved in the U.S. for the treatment of adults with TD in 2017. In contrast, valbenazine received approval in Japan for the treatment of TD in 2022. These potential barriers related to diagnosis, timely treatment, and monitoring of TD may limit the demand for tardive dyskinesia therapeutics, restricting the market growth.
Single Drug Availability Led to Dominance of Valbenazine Segment in 2022
By drug, the market is segmented into valbenazine, deutetrabenazine, and others.
The valbenazine segment dominated the Japan tardive dyskinesia therapeutics market share in 2022. In Japan, only valbenazine is approved for the treatment of this disease. In March 2022, Neurocrine Biosciences, Inc., in collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC), obtained the regulatory approval of DYSVAL capsules 40 mg (valbenazine) for the treatment of tardive dyskinesia from the Japanese Ministry of Health, Labour and Welfare. The growing focus of valbenazine manufacturers on collaborations with domestic players of Japan is majorly driving the growth of the segment. Moreover, its inclusion in the National Health Insurance Drug Price List has contributed to its future growth prospects.
Deutetrabenazine has not received approval in Japan for this disease till date. The use of deutetrabenazine has demonstrated significant improvements in the abnormal involuntary movement of patients suffering from this disease. Patients on deutetrabenazine have also demonstrated a safe and efficacious profile in its long-term use. These factors indicate that there are significant prospects for its approval in the near future.
Pipeline candidates are included in the others segment, which are estimated to be launched at the end of the forecast period. The rising prevalence of this disease is contributing to an increase in investment in the research and development of new drug candidates from established market players. This rising prevalence and growing awareness have brought opportunities for many new entrants to introduce new and innovative treatment options to the market, leading to its growth.
To know how our report can help streamline your business, Speak to Analyst
Higher Distribution through Hospital Pharmacies Contributed to the Segment’s Dominance in 2022
On the basis of distribution channel, the market is classified into retail pharmacies and hospital pharmacies.
The hospital pharmacies segment accounted for the largest share of the market in 2022 due to the need to procure prescription tardive dyskinesia therapeutics from hospital pharmacies. Pharmaceutical drug products in Japan are mainly categorized into OTC drugs and ethical drugs. Most of the ethical drugs in Japan are distributed from pharmaceutical manufacturers to wholesalers and then supplied to hospitals and clinics in the nation. Drugs available for the treatment of this condition are prescription drugs and, hence, are likely to be distributed by hospital pharmacies, subsequently driving the segment growth.
The retail pharmacies segment is projected to grow comparatively at a lower CAGR over the study period. The increasing number of patient footfall seeking the treatment of neurological disorders is primarily driving the growth of the segment in the market. Moreover, an increase in the prescription rate of antipsychotics for the treatment of various psychotic disorders is contributing to the rising prevalence of this disease among the Japanese population. This contributes to an increase in the number of patients visiting their nearest pharmacist for their repeated dose.
Sole Regulatory Approval Belonging to Mitsubishi Tanabe Pharma Corporation Led to its Market Monopoly in 2022
In terms of the competitive landscape, the market for tardive dyskinesia therapeutics in Japan was dominated by the Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corporation). In the Japanese market, only valbenazine is approved for the treatment of this disease, which has led to its dominance in 2022. The company is focused on expanding its product presence across Asian countries by getting regulatory approvals for this disease.
Teva Pharmaceutical Industries Ltd. is likely to hold some share of the Japan tardive dyskinesia therapeutics market during the forecast period. The company’s product, Austedo (deutetrabenazine), is a deuterated drug, and the guidelines related to these drugs are inconsistent and are at a very nascent stage in the Japanese market. There are limited R&D investments for the treatment of this disease in the market. Some of the market players, such as Luye Pharma Group, which has a geographical presence in Japan, are investing in accelerating the development of its pipeline candidate for this indication, which is expected to capture some share by the end of the forecast period.
An Infographic Representation of Japan Tardive Dyskinesia Therapeutics Market
To get information on various segments, share your queries with us
The Japan tardive dyskinesia therapeutics market research report provides qualitative and quantitative insights into the market and a detailed analysis of the market size and growth rate for all possible segments. In addition to this, the report provides a detailed analysis of the market dynamics and competitive landscape. Various key insights presented in the report are the prevalence of the disease, 2022, pipeline analysis, key industry developments by key players, regulatory and reimbursement scenario, economic cost burden for the treatment of the disease, and the impact of COVID-19 on the market.
CAGR of 22.7% from 2023 to 2030
Value (USD Million)
By Distribution Channel
Fortune Business Insights says that the market size was USD 24.3 million in 2022 and is projected to reach USD 162.1 million by 2030.
The market will grow at a CAGR of 22.7% over the forecast period (2023-2030).
By type, the valbenazine segment dominated the market in 2022.
The growing antipsychotic polypharmacy rate among psychiatric patients is increasing the number of patients experiencing tardive dyskinesia, which is one of the major factors driving the market.
Mitsubishi Tanabe Pharma Corporation is the major player in this market.
The rising prevalence of psychiatric disorders and increasing consumption of antipsychotic drugs, leading to growth in the prevalence of this disease, are expected to drive the demand for these drugs.
“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”- U.S.-based biotechnology company focussing on treatment of chronic pain.
“Kudos to your team. Thank you very much for your support and agility to answer our questions.”- Europe-based provider of solutions to automate data centre operations.
“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”- India-based manufacturer of industrial and specialty intermediates with a strong global presence.
“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”- One of the largest cosmetics company in the world.
“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”- U.S. based startup operating in the cultivated meat market.
“We received the below report on the U.S. market from you. We were very satisfied with the report.”- Global hearing aids manufacturer.
“I just finished my first pass-through of the report. Great work! Thank you!”- U.S. based solar racking solutions provider.
“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”- World’s leading advisory firm.
“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”- Germany based machine construction company.
“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”- Japanese manufacturing company of stationery products.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry